ClinicalTrials.gg
Not yet recruitingNCT07947823ASTARUpdated Nov 19, 2026

ASTAR: Sacituzumab Govitecan For Breast Cancer

A Phase 2 interventional study of Sacituzumab Govitecan (SG) and Cyclophosphamide in Breast Cancer, HR Positive/HER-2 Negative Breast Cancer and High-risk Breast Cancer, sponsored by Massachusetts General Hospital. Not yet recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Massachusetts General Hospital · Phase 2, Interventional, and Treatment

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 66 studies in Breast Neoplasms by Massachusetts General Hospital — 12 open to participants now, 23 under way, none of them phase 3. Breast Neoplasms · Massachusetts General Hospital.

Planned enrollment
36th of 53
32 · median 51
Started
2027
with 2 others
Phase 2
11 of 66
2 open now
Primary completion
2028-09
later than 19 of 22 live
Registered
66th of 66
by date

Among the 66 studies in Breast Neoplasms by Massachusetts General Hospital, this one is the 36th largest by planned enrollment of the 53 interventional ones that give a count, is one of 3 that started in 2027, is one of 11 in phase 2, reaches primary completion later than 19 of the 22 other live ones, and was the 66th registered.

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

12 of the 66 studies in Breast Neoplasms by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies in Breast Neoplasms by Massachusetts General Hospital, or all of them as a file.
02

Study summary

The goal of this clinical trial is to assess the safety and tolerability of sacituzumab govitecan followed by docetaxel and cyclophosphamide for individuals with high-risk early-stage HR+/HER2- breast cancer. The main questions it aims to answer are:

  • Is sacituzumab govitecan safe for individuals with this type of cancer?
  • Is sacituzumab govitecan effective in curing this type of cancer? Participants will receive up to 8 cycles of sacituzumab govitecan with chemotherapy.
Read the detailed description

This is a single-arm, open-label, phase II study evaluating the toxicity and feasibility of sacituzumab govitecan (SG) followed by docetaxel/cyclophosphamide (TC) in patients with high-risk early-stage HR+/HER2- breast cancer. Participants will receive four 21-day cycles of the study treatment, sacituzumab govitecan, and then four 21-day cycles of docetaxel and cyclophosphamide chemotherapy, for a total of eight cycles or 24 weeks. Participants will be followed for up to three years after completing study treatment. It is expected that about 32 people will take part in this research study. Gilead Sciences, Inc., a biopharmaceutical company, is supporting this research study by providing the study drug, sacituzumab govitecan, and funding for research activities. The U.S. Food and Drug Administration (FDA) has not approved sacituzumab govitecan for this specific disease, but it has been approved for use in other stages of breast cancer. Sacituzumab govitecan is a lab-made, humanized monoclonal antibody drug-conjugate. "Humanized" means it is primarily made to look like a natural human antibody, so the body tolerates it better. An antibody is a protein made by your immune system that recognizes and sticks to harmful things like bacteria, viruses, or cancer cells so your body can fight them off. Sacituzumab govitecan is a type of targeted cancer treatment made by linking an antibody that fights cancer cells and a chemotherapy drug that can kill the cancer cells together. Use of an antibody allows the chemotherapy to be delivered directly to cancer cells, helping kill them while reducing damage to the rest of the body. The U.S. FDA has approved docetaxel and cyclophosphamide chemotherapy as a treatment option for this disease. Docetaxel is a type of chemotherapy that works by disrupting the function of microtubules (a hollow "tube" that helps cells keep their shape and pull apart) which helps to stop cell division. Cyclophosphamide is an alkylating agent, a type of chemotherapy medication that works by adding alkyl groups to DNA. Alkyl groups are small chemical pieces that attach to other molecules and change how those molecules work. This interferes with the cells' ability to make copies of itself, causing cell death in rapidly dividing cells, such as cancer cells. Together, docetaxel essentially "freezes" cells so they can't finish dividing and cyclophosphamide damages their DNA so they cannot make new copies, eventually leading to cell death. Using these drugs together helps attack leftover cancer cells in different ways at the same time, helping the treatment to be more effective and killing cancer cells. The U.S. FDA has not approved sacituzumab govitecan followed by docetaxel and cyclophosphamide chemotherapy as a treatment option for this disease.

03

Conditions studied

  • Breast Cancer
  • HR Positive/HER-2 Negative Breast Cancer
  • High-risk Breast Cancer
  • Early-Stage Breast Cancer

Browse trials for

Keywords

  • breast cancer
  • early-stage
  • high-risk
  • HR+/HER2-
  • ASTAR
  • sacituzumab govitecan
  • chemotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female or male patients ≥ 18 years of age.
  • confirmed diagnosis of invasive breast cancer after completion of definitive surgical management (either mastectomy or lumpectomy) within 3-12 weeks of starting study treatment.
  • Participants must have proven hormone receptor positive (HR+) (either/both estrogen receptor (ER) and progesterone receptor (PR) positive) negative (HER2-), invasive breast cancer. ER, PR, and HER2 positivity will be determined per ASCO/CAP guidelines by institutional (local) assessment, with expression of either the estrogen receptor (ER) or progesterone receptor (PR) at least 10%. Patients with multi-focal and multi-centric disease are eligible provided all histologically examined lesions are HR+/HER2- (local assessment). The need to biopsy additional lesions is per the discretion of the treating physician. Patients with bilateral invasive breast cancer are eligible provided all histologically examined lesions are HR+/HER2- (local assessment).
  • Anatomic stage IIB-III breast cancer according to AJCC 8th edition TNM staging, based on final surgical pathology. Patients with only lymph node micrometastases (pN1mi) are not eligible. Participants must have no evidence of distant disease (M0). Staging scans are not required and may be obtained at the discretion of the treating physician.
  • Both pre- and women are eligible.
  • performance status = 0, 1, 2 ( ≥60%, see Appendix A)
  • Ability to understand and the willingness to sign a written form (ICF). Patient has signed the ICF prior to any screening procedures being performed and is able to comply with protocol requirements.
  • Patient has adequate bone marrow and organ function as defined by the following laboratory values at screening:
  • (ANC) ≥ 1,500 per mm3
  • ≥ 100,000 per mm3
  • ≥9.0 g/dL
  • ≤1.5
  • Serum creatinine \<1.5 mg/dL or ≥50 mL/min
  • (ALT) and aspartate aminotransferase (AST) \<2.5 x
  • Total ≤1.5 x ULN or in patients with well-documented Gilbert's Syndrome direct bilirubin ≤1.5 x ULN

Exclusion criteria

Exclusion Criteria:

  • Inflammatory breast cancer or locally recurrent breast cancer
  • Participants currently receiving systemic therapy, including endocrine therapy, for any other or having received systemic therapy for a malignancy in the past 3 years
  • Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • , uncontrolled heart disease and/or cardiac repolarization abnormality including any of the following:
  • History of angina pectoris, symptomatic pericarditis, coronary artery bypass graft (CABG) or myocardial infarction within 6 months prior to study entry
  • History of cardiac failure, known cardiomyopathy ( \< 50%; new LVEF assessment is not specifically required for this trial), significant/symptomatic bradycardia, Long syndrome, family history of idiopathic sudden death or congenital long QT syndrome or any of the following:
  • Known risk to prolong the QT interval or induce Torsade's de Pointes.
  • Uncorrected hypomagnesemia or hypokalemia.
  • Systolic Blood Pressure (SBP) >160 mmHg or \<90 mmHg.
  • Bradycardia (heart rate \<50 at rest), by or pulse. On screening, inability to determine the QTcF interval on the ECG (i.e.: unreadable or not interpretable) or QTcF >470 screening ECG
  • Pregnant or breast-feeding women are excluded from this study because the safety of study regimen in this population is not established
  • Participants with well-controlled infection are eligible if they are on stable antiretroviral therapy and have no evidence of uncontrolled infection. Participants with chronic infection are eligible if viral replication is adequately suppressed with antiviral therapy when indicated. Participants with infection are eligible if they have been successfully treated or have stable disease with no evidence of clinically significant hepatic dysfunction. Separate HIV, hepatitis B, or hepatitis C testing for this trial is not required unless clinically indicated.
  • Participants who are currently receiving chronic treatment with at a dose ≥ 10 mg of prednisone (or its glucocorticoid equivalent) per day (inhaled and topical steroids are allowed), or any other chronic treatment that cannot be discontinued prior to starting study drug
  • Participants who are not good candidates for the study (as per investigator judgement)
  • Women of , defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of throughout the study and for 6 months after the last dose of sacituzumab govitecan, 2 months after the last dose of docetaxel, and for 1 year after the last dose of cyclophosphamide. Male participants capable of impregnating a woman must use highly effective methods of contraception throughout the study and for 3 months after the last dose of sacituzumab govitecan and for 4 months after the last doses of docetaxel and cyclophosphamide. Women are considered and not of childbearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of childbearing potential. Barrier method plus spermicide alone is not considered highly effective contraception but could be combined with other highly effective contraception methods. Highly effective contraception methods include:
  • Total abstinence when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
  • Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment
  • Use of oral, injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal contraception that have comparable efficacy (failure rate \<1%), for example hormone vaginal ring or transdermal hormone contraception
  • Prior treatment involving topoisomerase-I targeting agents, including ADCs
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Sacituzumab Govitecan with Chemotherapy

    Participants will be given sacituzumab govitecan (SG) at a pre-determined dose on days 1 and 8 of each 21-day cycle into their vein (by intravenous infusion). This will continue for up to 4 cycles. After completing 4 cycles of SG, participants will be given docetaxel and cyclophosphamide chemotherapy at the pre-determined doses on day 1 of each 21-day cycle into their vein. This will continue for up to 4 cycles, for a total of 8 treatment cycles from the start of treatment with SG.

    Drug: Sacituzumab Govitecan (SG) · Drug: Cyclophosphamide · Drug: Docetaxel

Interventions

  • DrugSacituzumab Govitecan (SG)

    Intravenous infusion administered on days 1 and 8 of cycles 1-4 (one cycle is 21 days).

  • DrugCyclophosphamide

    Intravenous infusion administered on day 1 of cycles 5-8 (one cycle is 21 days).

  • DrugDocetaxel

    Intravenous infusion administered on day 1 of cycles 5-8 (one cycle is 21 days).

06

What researchers measure

Primary outcomes

  1. Incidence of Grade 3 or Higher Treatment-Emergent Adverse Events (TEAEs)

    TEAEs are defined/graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE); version in effect at study initiation. The proportion of patients experiencing at least 1 grade 3 or higher TEAE will be summarized both as a point estimate and by its respective 95% confidence interval. Statistical significance is declared at the one-sided 5% type I error by a two-stage binomial test. In addition to the estimation of the one-side 95% confidence interval around the grade 3 or higher TEAE rate, equivalent two-sided 90% confidence intervals will be estimated for better clinical interpretability.

    Time frame: Screening to 2 years after completion of protocol therapy or until death, whichever occurs first.

Secondary outcomes

  1. Proportion of Patients who Complete the Planned Study Regimen (Tolerability)

    Tolerability is defined as the proportion of patients who complete the planned study regimen without premature discontinuation due to toxicity. The completion rate and exact two-sided 95% confidence intervals will be reported. If all 32 patients are enrolled, the maximum half-width of the 95% confidence interval is approximately +/-0.18. Reasons for dose-reduction, delay, or discontinuation will be summarized.

    Time frame: Day first participant is enrolled to 2 years after the last participant completes protocol therapy.

  2. 2-Year Recurrence-Free Survival (RFS)

    RFS is defined as the time from treatment initiation to documented invasive breast cancer recurrence (local, regional, or distant) or death from any cause, whichever occurs first. Participants alive without disease recurrence will be censored at the date of last disease evaluation. The 2-year RFS rate will be estimated using the Kaplan-Meier method. Given the short follow-up window and long duration of response of these patients, median RFS may not be achieved, at which point the probability for being recurrence free for 2 years will be estimated along with its respective 95% confidence interval (CI). Assuming 90% of the subjects are recurrence free at 2 years, the 95% CI is expected to extend approximately 17 percentage points below and 7 percentage points about the point estimate (approximately 73%-97%). Assuming an 80% 2-year RFS, the 95% CI is expected to extend approximately 18 percentage points below and 10 percentage points about the point estimate (approximately 62%-90%).

    Time frame: Day 1 of cycle 1 (each cycle is 21 days) to 2 years after day 1 of cycle 1, day of documented disease recurrence, or death, whichever occurs first.

  3. Changes in Circulating tumor DNA (ctDNA) During and After Administration of Study Therapy

    ctDNA will be analyzed longitudinally during treatment and follow-up using a general linear mixed model with a random intercept per subject and at minimum a fixed effect for time. ctDNA positively rates at predefined time points will be estimated and summarized. Changes in ctDNA allele fraction or tumor fraction over time will be summarized by slope and intercept estimates from the mixed model. 95% confidence interval will also be reported from the model.

    Time frame: Screening to 2 years after completion of protocol therapy or until death, whichever occurs first.

07

Study locations

5 sites
08

References and documents

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Request may be directed to: Dr. Laura Spring at 617-726-6500 or LSpring@mgh.harvard.edu. The protocol and statistical analysis plan will be made available on ClinicalTrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data can be shared no earlier than 1 year following the date of publication.

Access criteria: Contact the Partners Innovations team at http://www.partners.org/innovation

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2027; primary completion for Sep 2028, 16 months later.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 16 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2026
First posted
Nov 19, 2026
StartEst.
Apr 21, 2027
Primary completionEst.
Sep 1, 2028
CompletionEst.
Sep 1, 2030
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07947823
Collaborators
Gilead Sciences
Responsible party
Laura M. Spring, MD (Principal Investigator, Massachusetts General Hospital) — Principal investigator
First posted
Nov 19, 2026
Start date
Apr 21, 2027 (estimated)
Primary completion
Sep 1, 2028 (estimated)
Completion
Sep 1, 2030 (estimated)
Last update
Nov 19, 2026

Study contacts

Laura Spring, MD
Contact
LSpring@mgh.harvard.edu
617-726-6500
Laura Spring, MD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion